{"id":542777,"date":"2021-05-11T18:50:01","date_gmt":"2021-05-11T18:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542777"},"modified":"2021-05-11T18:50:01","modified_gmt":"2021-05-11T18:50:01","slug":"nonalcoholic-steatohepatitis-nash-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nonalcoholic-steatohepatitis-nash-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_542777.html","title":{"rendered":"Non-Alcoholic Steatohepatitis (NASH) Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight"},"content":{"rendered":"
\"Non-Alcoholic<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201cNon-Alcoholic Steatohepatitis (NASH) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Non-Alcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Non-Alcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Non-Alcoholic Steatohepatitis (NASH)- Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/strong><\/p>\n

DelveInsight’s<\/span> “Non-Alcoholic Steatohepatitis (NASH) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″<\/span> report delivers an in-depth understanding of the  Non-Alcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the  Non-Alcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/span><\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. \n

    Of all the prevalent cases of NAFLD in the 7MM, approximately <\/span>19%<\/span> of the population fulfilled the criteria for NASH. These cases are expected to increase throughout the study period [2018–2030].<\/span><\/p>\n<\/li>\n

  2. \n

    We estimate the highest prevalence of NASH in the United States, accounting for close to <\/span>50% <\/span>of the total prevalent cases, followed by Japan.<\/span><\/p>\n<\/li>\n

  3. \n

    On the other hand, it is assessed that among the <\/span>European countries<\/span>, Germany accounted for the highest prevalent population, followed by Italy. Among all the 7MM countries, Spain had the lowest prevalent population.<\/span><\/p>\n<\/li>\n<\/ol>\n

    Key benefits of the report<\/strong>:<\/span><\/p>\n

    1. Non-Alcoholic Steatohepatitis (NASH) market report covers a descriptive overview and comprehensive insight of the Non-Alcoholic Steatohepatitis (NASH) epidemiology and Non-Alcoholic Steatohepatitis (NASH) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/span><\/p>\n

    2. Non-Alcoholic Steatohepatitis (NASH) market report provides insights on the current and emerging therapies.<\/span><\/p>\n

    3. Non-Alcoholic Steatohepatitis (NASH) market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/span><\/p>\n

    4. The Non-Alcoholic Steatohepatitis (NASH) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Non-Alcoholic Steatohepatitis (NASH) market.<\/span><\/p>\n

    Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/nonalcoholic-steatohepatitis-nash-market<\/span><\/a><\/strong><\/p>\n

    Non-Alcoholic Steatohepatitis (NASH): Overview<\/strong><\/p>\n

    Non-alcoholic steatohepatitis (NASH) is an advanced form of <\/span>non-alcoholic fatty liver disease (NAFLD)<\/span>. NAFLD is caused by a buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called <\/span>cirrhosis<\/span><\/p>\n

    The key players involved in Non-Alcoholic Steatohepatitis (NASH) market:<\/strong><\/a><\/p>\n

      \n
    1. \n

      Enyo Pharma<\/span><\/p>\n<\/li>\n

    2. \n

      Terns Pharmaceuticals<\/span><\/p>\n<\/li>\n

    3. \n

      Ascletis Pharma<\/span><\/p>\n<\/li>\n

    4. \n

      Oramed Pharmaceuticals<\/span><\/p>\n<\/li>\n

    5. \n

      Can-Fite BioPharma<\/span><\/p>\n<\/li>\n

    6. \n

      Inventiva Pharma<\/span><\/p>\n<\/li>\n

    7. \n

      Madrigal Pharmaceuticals<\/span><\/p>\n<\/li>\n

    8. \n

      MediciNova<\/span><\/p>\n<\/li>\n

    9. \n

      TaiwanJ Pharmaceuticals<\/span><\/p>\n<\/li>\n<\/ol>\n

      The launch of the emerging therapies is expected to significantly impact the  Non-Alcoholic Steatohepatitis (NASH) treatment scenario in the upcoming years:-<\/strong><\/p>\n

      Drug covered<\/strong><\/p>\n

        \n
      1. \n

        EYP001<\/span><\/p>\n<\/li>\n

      2. \n

        TERN-101<\/span><\/p>\n<\/li>\n

      3. \n

        ASC40<\/span><\/p>\n<\/li>\n

      4. \n

        ORMD-0801<\/span><\/p>\n<\/li>\n

      5. \n

        Namodenoson (CF102)<\/span><\/p>\n<\/li>\n

      6. \n

        Lanifibranor (IVA33)<\/span><\/p>\n<\/li>\n

      7. \n

        Resmetirom (MGL-3196)<\/span><\/p>\n<\/li>\n

      8. \n

        MN-001 (Tipelukast)<\/span><\/p>\n<\/li>\n

      9. \n

        JKB-122<\/span><\/p>\n<\/li>\n<\/ol>\n

        Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/nonalcoholic-steatohepatitis-nash-market<\/span><\/a><\/strong><\/p>\n

        Table of Contents<\/strong><\/p>\n

        1. Report Introduction<\/span><\/p>\n

        2. Executive Summary<\/span><\/p>\n

        3. SWOT analysis<\/span><\/p>\n

        4. Non-Alcoholic Steatohepatitis (NASH) Patient Share (%) Overview at a Glance<\/span><\/p>\n

        5. Non-Alcoholic Steatohepatitis (NASH) Market Overview at a Glance<\/span><\/p>\n

        6. Non-Alcoholic Steatohepatitis (NASH) Disease Background and Overview<\/span><\/p>\n

        7. Non-Alcoholic Steatohepatitis (NASH) Epidemiology and Patient Population<\/span><\/p>\n

        8. Country-Specific Patient Population of  Non-Alcoholic Steatohepatitis (NASH)<\/span><\/p>\n

        9. Non-Alcoholic Steatohepatitis (NASH) Current Treatment and Medical Practices<\/span><\/p>\n

        10. Unmet Needs<\/span><\/p>\n

        11. Non-Alcoholic Steatohepatitis (NASH) Emerging Therapies<\/span><\/p>\n

        12. Non-Alcoholic Steatohepatitis (NASH) Market Outlook<\/span><\/p>\n

        13. Country-Wise  Non-Alcoholic Steatohepatitis (NASH) Market Analysis (2017–2030)<\/span><\/p>\n

        14. Market Access and Reimbursement of Therapies<\/span><\/p>\n

        15. Market drivers<\/span><\/p>\n

        16. Market barriers<\/span><\/p>\n

        17. Appendix<\/span><\/p>\n

        18. Non-Alcoholic Steatohepatitis (NASH) Report Methodology<\/span><\/p>\n

        19. DelveInsight Capabilities<\/span><\/p>\n

        20. Disclaimer<\/span><\/p>\n

        21. About DelveInsight<\/span><\/p>\n

        Related Reports:<\/strong><\/p>\n

        Non-Alcoholic Steatohepatitis (NASH)- Pipeline Insights, 2021<\/strong><\/p>\n

        “<\/span>Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight, 2021<\/span>” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Non-Alcoholic Steatohepatitis (NASH) market. A detailed picture of the Non-Alcoholic Steatohepatitis (NASH) pipeline landscape is provided, which includes the disease overview and Non-Alcoholic Steatohepatitis (NASH) treatment guidelines.<\/span><\/p>\n

        Media Contact<\/span>
        Company Name:<\/strong>         DelveInsight Business Research LLP<\/a>
        Contact Person:<\/strong> Kritika Rehani
        Email:<\/strong>         Send Email<\/a>
        Phone:<\/strong> 9193216187
        Address:<\/strong>304 S. Jones Blvd #2432
        City:<\/strong> Las Vegas
        State:<\/strong> Nevada
        Country:<\/strong> United States
        Website:<\/strong>         https:\/\/www.delveinsight.com\/<\/a><\/p>\n

        <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

        DelveInsight Business Research LLP DelveInsight\u2019s \u201cNon-Alcoholic Steatohepatitis (NASH) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Non-Alcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Non-Alcoholic Steatohepatitis (NASH) market trends in the … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542777","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542777","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542777"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542777\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542777"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542777"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542777"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}